All patients
age >= 60 yr corticosteroids: no corticosteroids: yes subjects at risk
sofosbuvir and daclatasvir in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Mobarak (DISCOVER), 2021 1.15 [0.83; 1.59]
Mobarak S (DISCOVER), 2021 1.10 [0.77; 1.57]
1.13 [0.89 ; 1.43 ] Mobarak (DISCOVER), 2021, Mobarak S (DISCOVER), 2021 2 0% 2,166 low not evaluable deathsdetailed results Mobarak (DISCOVER), 2021 1.15 [0.83; 1.59]
Mobarak S (DISCOVER), 2021 1.15 [0.80; 1.67]
Sadeghi , 2020 0.56 [0.12; 2.56]
Yakoot, 2020 0.38 [0.07; 2.08]
1.11 [0.87 ; 1.40 ] Mobarak (DISCOVER), 2021, Mobarak S (DISCOVER), 2021, Sadeghi , 2020, Yakoot, 2020 4 0% 2,321 low not evaluable clinical improvement (14-day)detailed results Sadeghi , 2020 3.63 [1.02; 12.93]
3.63 [1.02 ; 12.93 ] Sadeghi , 2020 1 0% 66 NA not evaluable hospital dischargedetailed results Mobarak (DISCOVER), 2021 1.01 [0.95; 1.08]
1.01 [0.95 ; 1.08 ] Mobarak (DISCOVER), 2021 1 0% 1,083 NA not evaluable mechanical ventilationdetailed results Mobarak S (DISCOVER), 2021 1.52 [0.72; 3.19]
Sadeghi , 2020 0.37 [0.09; 1.58]
Yakoot, 2020 0.38 [0.07; 2.08]
0.73 [0.25 ; 2.10 ] Mobarak S (DISCOVER), 2021, Sadeghi , 2020, Yakoot, 2020 3 53% 1,238 moderate not evaluable ICU admissiondetailed results Yakoot, 2020 0.38 [0.07; 2.08]
0.38 [0.07 ; 2.08 ] Yakoot, 2020 1 0% 89 NA not evaluable recoverydetailed results Mobarak S (DISCOVER), 2021 0.97 [0.89; 1.05]
Yakoot, 2020 1.60 [1.00; 2.55]
1.18 [0.73 ; 1.90 ] Mobarak S (DISCOVER), 2021, Yakoot, 2020 2 76% 1,172 moderate not evaluable serious adverse eventsdetailed results Sadeghi , 2020 1.00 [0.02; 51.94]
Yakoot, 2020 1.02 [0.02; 52.72]
1.01 [0.06 ; 16.47 ] Sadeghi , 2020, Yakoot, 2020 2 0% 155 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 08:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 815
- roots T: 290